Atara Biotherapeutics Inc. is selling $150 million of its common shares in an underwritten public offering.
The company also expects to grant the underwriters an option to buy up to an additional $22.5 million of common shares.
J.P. Morgan and Cowen are acting as joint book-running managers for the proposed offering.
